Northern Trust
KROS icon

Northern Trust’s Keros Therapeutics KROS Stock Holding History

Northern Trust’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.65M Sell
153,843
-100,344
-39% -$1.12M ﹤0.01% 3246
2026
Q1 		$2.81M Buy
254,187
+3,616
+1% +$55.8K ﹤0.01% 2789
2025
Q4 		$5.1M Sell
250,571
-82,187
-25% -$1.44M ﹤0.01% 2468
2025
Q3 		$5.26M Buy
332,758
+59,635
+22% +$881K ﹤0.01% 2470
2025
Q2 		$3.65M Sell
273,123
-16,888
-6% -$228K ﹤0.01% 2649
2025
Q1 		$2.96M Sell
290,011
-6,456
-2% -$75K ﹤0.01% 2704
2024
Q4 		$4.69M Buy
296,467
+30,111
+11% +$1.56M ﹤0.01% 2542
2024
Q3 		$15.5M Buy
266,356
+29,868
+13% +$1.48M ﹤0.01% 1796
2024
Q2 		$10.8M Buy
236,488
+850
+0.4% +$45.7K ﹤0.01% 1948
2024
Q1 		$15.6M Buy
235,638
+18,792
+9% +$1.11M ﹤0.01% 1762
2023
Q4 		$8.62M Buy
216,846
+3,947
+2% +$124K ﹤0.01% 2160
2023
Q3 		$6.79M Buy
212,899
+9,216
+5% +$344K ﹤0.01% 2255
2023
Q2 		$8.18M Buy
203,683
+26,413
+15% +$1.16M ﹤0.01% 2207
2023
Q1 		$7.57M Buy
177,270
+2,506
+1% +$127K ﹤0.01% 2207
2022
Q4 		$8.39M Buy
174,764
+11,817
+7% +$552K ﹤0.01% 2127
2022
Q3 		$6.13M Buy
162,947
+12,446
+8% +$431K ﹤0.01% 2333
2022
Q2 		$4.16M Buy
150,501
+1,984
+1% +$87.1K ﹤0.01% 2623
2022
Q1 		$8.08M Sell
148,517
-5,655
-4% -$290K ﹤0.01% 2281
2021
Q4 		$9.02M Buy
154,172
+4,552
+3% +$227K ﹤0.01% 2306
2021
Q3 		$5.92M Sell
149,620
-5,318
-3% -$189K ﹤0.01% 2625
2021
Q2 		$6.58M Buy
154,938
+27,068
+21% +$1.47M ﹤0.01% 2663
2021
Q1 		$7.87M Sell
127,870
-7,371
-5% -$467K ﹤0.01% 2458
2020
Q4 		$9.54M Buy
135,241
+51,895
+62% +$3.27M ﹤0.01% 2277
2020
Q3 		$3.21M Sell
83,346
-4,309
-5% -$171K ﹤0.01% 2799
2020
Q2 		$3.29M Buy
+87,655
New +$2.7M ﹤0.01% 2767

Other funds holding KROS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Northern Trust's KROS Position: Q2 2026 in Review

Northern Trust reduced its Keros Therapeutics (KROS) stake by 39% in Q2 2026, selling an estimated $1.12M and leaving 153,843 shares worth $1.65M. The position accounts for ﹤0.01% of the portfolio, ranked #3246.

Northern Trust first reported a position in KROS in Q2 2020 and has held it in 25 quarters since. The position peaked at $15.6M in Q1 2024. 132 funds tracked by Wall St. Rank hold KROS as of Q2 2026.

  • Northern Trust held 153,843 shares of Keros Therapeutics worth $1.65M as of Q2 2026.
  • Northern Trust sold 100,344 Keros Therapeutics shares in Q2 2026, an estimated $1.12M.
  • Keros Therapeutics made up ﹤0.01% of Northern Trust's portfolio in Q2 2026, its #3246 holding.
  • Northern Trust first reported a position in Keros Therapeutics in Q2 2020 and has held it in 25 quarters since.
  • Northern Trust's Keros Therapeutics position peaked at $15.6M in Q1 2024.
  • 132 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2026.

Based on Northern Trust's 13F filing for Q2 2026, filed 13 Aug 2026.